Lille

• GYNET : A randomized, multicenter, open label, Phase I/II study to evaluate the safety (Phase I - safety run in), clinical and biological ac … Ended recruitment
  2024-510714-32-00 4 2020-12-10 Patiens with locally advanced/metastatic endometrial carcinoma or cerv
• TALAMESO : A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-ba … Ended recruitment
  2024-514104-14-00 4 2020-11-04 Adults subjects with advanced malignant pleural (cohort A) or peritone
• A Study of Atezolizumab with or without Tiragolumab in Participants with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have … Ended recruitment
  2022-502052-30-00 5 2020-10-27 Unresectable Esophageal Squamous Cell Carcinoma
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
• Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended recruitment
  2023-504805-35-00 9 2020-10-22 Lymphoma of B-cell origin
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended recruitment
  2023-506365-64-00 5 2020-10-16 Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in … Ended recruitment
  2023-505812-39-00 5 2020-08-28 HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
• A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexametha … Ended recruitment
  2023-506588-32-00 5 2020-06-12 Relapsed and Lenalidomide-Refractory Multiple Myeloma
• A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer Ended recruitment
  2023-506782-56-00 5 2020-03-10 RET-Mutant Medullary Thyroid Cancer
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in … Ended recruitment
  2024-518069-89-00 4 2020-02-03 Patients with solid cancers
• An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma Ended recruitment
  2023-506587-13-00 4 2020-01-30 Multiple Myeloma
• The TARGET BP I Ended recruitment
  2024-512525-83-00 5 2020-01-07 Hypertension
• Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or withou … Ended recruitment
  2023-509049-11-00 5 2020-01-01 FIGO stage III ovarian cancer who are eligible for primary cytoreducti
• A clinical study evaluating the benefits of apalutamide, a novel drug targeting prostate cancer growth, in combination with radiotherapy and … Ended recruitment
  2024-514829-36-00 5 2019-12-02 High-risk biochemically-relapsed prostate adenocarcinoma following rad
• Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch … Ended recruitment
  2022-502354-14-00 5 2019-10-28 Completely resected Stage IIb/c melanoma
• Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive, … Ended recruitment
  2024-516847-23-00 4 2019-08-27 ER-positive and HER2-negative metastatic or locally advanced breast ca
• A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 targeted 4-1BB l … Ended recruitment
  2022-502616-37-00 9 2019-07-30 Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)
• Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin wi … Ended recruitment
  2024-515946-17-00 5 2019-07-22 Non Small Cell Lung Cancer
• A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as pre-operative treatment f … Ended recruitment
  2024-514705-62-00 5 2019-07-08 Recurrent rectal cancer after local excision
• A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk … Ended recruitment
  2023-505223-31-00 4 2019-06-14 Localized ER+ breast cancer
• Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer Ended recruitment
  2024-512165-13-00 4 2019-05-13 Localised unresectable adenocarcinoma or squamous cell carcinoma of th
• Phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer considering two different … Ended recruitment
  2024-514706-31-01 5 2019-05-02 Epithelial ovarian cancer, Fallopian tube ovarian cancer, Peritoneal o
• Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended recruitment
  2023-506921-12-00 5 2018-12-27 ER+/HER2- Breast Cancer

Showing 505–528 of 686 trials